Trial reportPLoS neglected tropical diseases2019
Efficacy of China-made praziquantel for treatment of Schistosomiasis haematobium in Africa: A randomized controlled trial.
Trial report in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03133832 (Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of human schistosomiasis in various regions of Tanzania Mainland and Zanzibar: A systematic review and meta-analysis of studies conducted for the past ten years (2013-2023).PLoS neglected tropical diseases · 2024Pooled it
- Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs.Wellcome open research · 2020Pooled it
- Understanding the Feasibility to Implement Schistosomiasis Elimination Project Under China-Zimbabwe Cooperation: A Pilot Study Protocol.Journal of epidemiology and global health · 2025Article
- Diterpenoids with Schistosomula-Killing and Anti-Fibrosis Activities In Vitro from the Leaves ofMolecules (Basel, Switzerland) · 2024Article
- Selected micronutrient status of school-aged children at risk ofAfrican journal of laboratory medicine · 2023Article
- The Indispensability of Snail Control for Accelerating Schistosomiasis Elimination: Evidence from Zanzibar.Tropical medicine and infectious disease · 2022Article
- Assessment of awareness and knowledge of schistosomiasis among school-aged children (6-13 years) in the Okavango Delta, Botswana.Global health research and policy · 2022Article
- The Efficiency of Commercial Immunodiagnostic Assays for the Field Detection ofPathogens (Basel, Switzerland) · 2022Article
- Elimination of schistosomiasis in China: Current status and future prospects.PLoS neglected tropical diseases · 2021Article
- Parasitological Observation in Schoolchildren with Urogenital Schistosomiasis Following Treatment with Three Different Brands of Praziquantel.Journal of Korean medical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn the roadmap on the neglected tropical diseases (NTD) the World Health Organization (WHO) aims at attaining at least 75% coverage of preventive chemotherapy in pre-school and school-age children by 2020. A randomized controlled trial was used to compare the effectiveness of praziquantel in treating Schistosoma haematobium in Africa using two different sources for the drug, Merck Limited Partnership (KgaA), Germany and Nanjing Pharmaceutical Factory (NPF), China.
methodsMore than 6,000 participants testing positive for S. haematobium infection were enrolled from three villages (shehias) situated in the northern, middle and southern part of Pemba Island, Zanzibar. Applying criteria of inclusion and exclusion, resulted in a study population of 152 people (84 males, 68 females). A randomized controlled trial was conducted assigning participants to either praziquantel from NPF or Merck KGaA. After one month, the cure rate of S. haematobium and adverse events were compared to evaluate effectiveness. The ratio of male to female, the ratio of light/high infection intensity, and the average value of age were calculated between the two drug manufacturers. Chi-squared test and T-test were used for consistency analysis.
resultsOut of the total of 73 cases receiving praziquantel from NPF, the cure rate achieved was 97.3% (73/75), while the 74 cases receiving the drug from Merck KgaA reached a similar cure rate (96.1% or 74/77). There was no significant difference between the two outcomes (χ2 = 0.003, P = 0.956). Among the 75 patients treat, only one (a 16-years old female student), who had received the drug made in China had slight adverse reactions manifested as dizziness, headache and abdominal pain.
conclusionThe efficacy of China-made praziquantel does not differ significantly from praziquantel made by Merck KGaA in Germany.
trial registrationClinicalTrials.gov, NCT03133832.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.